Stockreport

Corcept Therapeutics: Despite FDA Blind Side, Relacorilant Remains A Viable Drug [Seeking Alpha]

Corcept Therapeutics Incorporated  (CORT) 
Last corcept therapeutics incorporated earnings: 2/20 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: corcept.com/investors
PDF Despite positive Phase 3 data, the FDA unexpectedly rejected CORT's NDA for Relacorilant, citing insufficient benefit-risk evidence. Korlym's ongoing revenues provide [Read more]